MY160732A - A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol - Google Patents
A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycolInfo
- Publication number
- MY160732A MY160732A MYPI2013000217A MYPI2013000217A MY160732A MY 160732 A MY160732 A MY 160732A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY 160732 A MY160732 A MY 160732A
- Authority
- MY
- Malaysia
- Prior art keywords
- stimulating factor
- granulocyte colony
- csf
- polyethylene glycol
- conjugate
- Prior art date
Links
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title abstract 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010133875/10A RU2446173C1 (ru) | 2010-08-13 | 2010-08-13 | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY160732A true MY160732A (en) | 2017-03-15 |
Family
ID=45567857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013000217A MY160732A (en) | 2010-08-13 | 2011-07-19 | A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol |
Country Status (18)
| Country | Link |
|---|---|
| KR (1) | KR101549457B1 (es) |
| CN (1) | CN103140499B (es) |
| CL (1) | CL2013000400A1 (es) |
| CO (1) | CO6670557A2 (es) |
| CR (1) | CR20130020A (es) |
| CU (1) | CU24139B1 (es) |
| DO (1) | DOP2013000003A (es) |
| EA (1) | EA019043B1 (es) |
| EC (1) | ECSP13012399A (es) |
| MA (1) | MA34525B1 (es) |
| MY (1) | MY160732A (es) |
| NI (1) | NI201300007A (es) |
| PE (1) | PE20131085A1 (es) |
| PH (1) | PH12012502426A1 (es) |
| RS (1) | RS20130094A1 (es) |
| RU (1) | RU2446173C1 (es) |
| SG (1) | SG187572A1 (es) |
| WO (1) | WO2012021088A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012110057A1 (en) | 2011-02-15 | 2012-08-23 | Chemisches Institut Schaefer Ag | Cefuroxime safety kit |
| EP2858636B1 (en) | 2012-06-07 | 2018-09-05 | Childrens Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
| CN103908427B (zh) * | 2013-01-05 | 2014-12-17 | 石药集团百克(山东)生物制药有限公司 | 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 |
| RU2535002C2 (ru) * | 2013-04-04 | 2014-12-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием |
| MX2016010699A (es) | 2014-02-18 | 2017-10-11 | Children's Hospital Los Angeles | Composiciones y metodos para tratar neutropenia. |
| US10519209B2 (en) * | 2014-07-14 | 2019-12-31 | Gennova Biopharmaceuticals Limited | Process for purification of rHu-GCSF |
| IL247369B (en) * | 2016-08-18 | 2018-08-30 | B G Negev Tech And Applications Ltd | Polypeptides derived from CSF-m and their uses |
| KR102020995B1 (ko) * | 2017-10-30 | 2019-09-16 | 한국코러스 주식회사 | 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법 |
| IL295406B1 (en) * | 2020-03-17 | 2026-06-01 | Drugrecure Aps | Liquid formulation of GM-CSF for inhalation |
| EP4121448A2 (en) * | 2020-03-20 | 2023-01-25 | Amgen Inc. | Determination of free n-terminus of pegfilgrastim using an acid protease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0401384B1 (en) * | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| KR20040083268A (ko) * | 2003-03-21 | 2004-10-01 | 한미약품 주식회사 | 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법 |
| RU2278870C2 (ru) * | 2004-08-30 | 2006-06-27 | Закрытое Акционерное Общество "Биокад" | Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе |
| CA2637569C (en) * | 2006-01-18 | 2013-01-08 | Yuhua Li | Pharmaceutical compositions with enhanced stability |
| US8840882B2 (en) * | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
-
2010
- 2010-08-13 RU RU2010133875/10A patent/RU2446173C1/ru active
-
2011
- 2011-07-19 WO PCT/RU2011/000532 patent/WO2012021088A1/en not_active Ceased
- 2011-07-19 CN CN201180044089.6A patent/CN103140499B/zh not_active Expired - Fee Related
- 2011-07-19 MY MYPI2013000217A patent/MY160732A/en unknown
- 2011-07-19 SG SG2013004544A patent/SG187572A1/en unknown
- 2011-07-19 PH PH1/2012/502426A patent/PH12012502426A1/en unknown
- 2011-07-19 RS RS20130094A patent/RS20130094A1/sr unknown
- 2011-07-19 MA MA35731A patent/MA34525B1/fr unknown
- 2011-07-19 CU CU20130012A patent/CU24139B1/es unknown
- 2011-07-19 PE PE2013000083A patent/PE20131085A1/es not_active Application Discontinuation
- 2011-07-19 KR KR1020137001860A patent/KR101549457B1/ko not_active Expired - Fee Related
- 2011-08-01 EA EA201101035A patent/EA019043B1/ru not_active IP Right Cessation
-
2013
- 2013-01-04 DO DO2013000003A patent/DOP2013000003A/es unknown
- 2013-01-18 CR CR20130020A patent/CR20130020A/es unknown
- 2013-01-18 CO CO13009151A patent/CO6670557A2/es unknown
- 2013-01-18 NI NI201300007A patent/NI201300007A/es unknown
- 2013-01-18 EC ECSP13012399 patent/ECSP13012399A/es unknown
- 2013-02-08 CL CL2013000400A patent/CL2013000400A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20130012A7 (es) | 2013-04-19 |
| RS20130094A1 (sr) | 2013-08-30 |
| WO2012021088A1 (en) | 2012-02-16 |
| DOP2013000003A (es) | 2013-07-31 |
| SG187572A1 (en) | 2013-03-28 |
| KR101549457B1 (ko) | 2015-09-02 |
| EA201101035A1 (ru) | 2012-02-28 |
| RU2446173C1 (ru) | 2012-03-27 |
| CU24139B1 (es) | 2015-12-23 |
| CN103140499A (zh) | 2013-06-05 |
| NI201300007A (es) | 2014-05-26 |
| KR20130043167A (ko) | 2013-04-29 |
| CO6670557A2 (es) | 2013-05-15 |
| PE20131085A1 (es) | 2013-10-10 |
| MA34525B1 (fr) | 2013-09-02 |
| CL2013000400A1 (es) | 2013-07-26 |
| CR20130020A (es) | 2013-02-20 |
| CN103140499B (zh) | 2014-12-17 |
| ECSP13012399A (es) | 2013-05-31 |
| PH12012502426A1 (en) | 2021-06-02 |
| EA019043B1 (ru) | 2013-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012502426A1 (en) | A novel conjugate of granulocyte colony-stimulating factor(g-csf) with polyethylene glycol | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| BR112013003045A2 (pt) | composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| MX2011008634A (es) | Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia. | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| MY149731A (en) | Compounds | |
| NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
| MY188598A (en) | Dexmedetomidine premix formulation | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
| MX2015004362A (es) | Derivados de ketamina. | |
| WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
| PH12014502619A1 (en) | Novel dosage and formulation | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| EP2682129A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous | |
| MX2015014905A (es) | Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos. | |
| CY1115600T1 (el) | Πιπεραζινες ως ανθελονοσιακοι παραγοντες | |
| PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
| BR112012020415A2 (pt) | composição farmacêutica para a prevenção ou tratamento da osteoartrite | |
| WO2015027669A3 (zh) | 苯基取代化合物及其药物组合物和应用 | |
| UA97076C2 (ru) | Мазь противовоспалительная на основе сульфаниламида |